WO1992007878A1 - Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 - Google Patents
Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 Download PDFInfo
- Publication number
- WO1992007878A1 WO1992007878A1 PCT/US1991/007910 US9107910W WO9207878A1 WO 1992007878 A1 WO1992007878 A1 WO 1992007878A1 US 9107910 W US9107910 W US 9107910W WO 9207878 A1 WO9207878 A1 WO 9207878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- human
- cell line
- gpl20
- antibodies
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 105
- 241000282414 Homo sapiens Species 0.000 title claims description 179
- 230000003472 neutralizing effect Effects 0.000 title claims description 53
- 210000004027 cell Anatomy 0.000 claims description 142
- 238000006386 neutralization reaction Methods 0.000 claims description 73
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 40
- 208000015181 infectious disease Diseases 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 108090000288 Glycoproteins Proteins 0.000 claims description 21
- 102000003886 Glycoproteins Human genes 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 20
- 230000002458 infectious effect Effects 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 14
- 210000005260 human cell Anatomy 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 description 38
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 25
- 230000002195 synergetic effect Effects 0.000 description 23
- 239000006228 supernatant Substances 0.000 description 22
- 238000002965 ELISA Methods 0.000 description 20
- 208000031886 HIV Infections Diseases 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000282579 Pan Species 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000006166 lysate Substances 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 238000010166 immunofluorescence Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 238000012286 ELISA Assay Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000282577 Pan troglodytes Species 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- LGGRPYXPOUIMKG-OJICBBQQSA-N (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)N LGGRPYXPOUIMKG-OJICBBQQSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100034349 Integrase Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 208000037357 HIV infectious disease Diseases 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000003754 fetus Anatomy 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011885 synergistic combination Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 101710091045 Envelope protein Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 230000006957 competitive inhibition Effects 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 101150026046 iga gene Proteins 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036436 anti-hiv Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 238000002967 competitive immunoassay Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701066 Bovine gammaherpesvirus 4 Species 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 101710205625 Capsid protein p24 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101710149279 Small delta antigen Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000010013 cytotoxic mechanism Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to antibodies ("Abs”) having neutralizing capabilities against HIV-1.
- the HIV envelope is composed of two glycoproteins, gpl20 and gp41. These glycoproteins are initially synthesized in virus-infected cells as a precursor called gpl60; this molecule is cleaved into gpl20 and gp41 prior to assembly of virions.
- LaRosa et al. (LaRosa et al. 1990) have recently shown that the V3 loop is less variable than originally thought, and, in addition, anti-V3 Abs with broader HIV strain specificity have been generated (Javaherian et al. 1990); these Abs recognize a conserved hexamer sequence (GPGRAF) present at the tip of the ->op.
- GPGRAF conserved hexamer sequence
- Three anti-V3 human monoclonal antibodies (HuMAbs) have been isolated by other investigators, and each is relatively strain-specific, recognizing only the MN strain of virus and closely related strains (Scott et al. 1990, Zolla-Pazner et al. 1990) .
- CD-4 binding site Another epitope cluster of HIV envelope that has been shown to elicit neutralizing antibodies is the CD-4 binding site of gpl20.
- CD-4 binding site is formed by non-contiguous protein loops from multiple regions of gpl20 (Olshevsky et al. 1990) .
- the precise structure of the CD-4 binding site and its contact residues have yet to be defined.
- Neutralizing antibodies against this site have been raised in some rodents (Sun et al. 1989, Lasky et al. 1987, Berman et al. 1989) using either recombinant gpl20 or linear peptides adjacent to one of the loops apparently forming the CD-4 binding site.
- chimpanzees were challenged with a stock of the IIIB strain of HIV that had previously been incubated with neutralizing serum Ab from an HIV-seropositive chimpanzee.
- the challenged animals were protected against viral infection, as assessed by lack of serum Ab response to virus and attempts at viral isolation (Emini et al. 1990) .
- Very recently, successful long term protection of two chimpanzees against HIV infection has been demons..rated by immunization with recombinant gpl60 followed by a V3 loop peptide (Girard et al. 1991) .
- Viral neutralization by combinations of rodent mAbs has been described for certain non-AIDS viruses, including rubella (Gerna et al. 1987) , vesicular stomatitis (Volk et al. 1982) , West Nile (Peiris et al. 1982), Sindbis (Clegg et al. 1983), Japanese encephalitis (Kimura-Kuroda and Yasui 1983), La Crosse (Kingsford 1984), Newcastle disease (Russell 1986) , respiratory syncytial (Anderson et al. 1988) , and bovine herpesvirus type 4 (Dubuisson et al. 1990) viruses.
- the present invention relates to a synergistic combination of certain antibodies specific for HIV-envelope glycoprotein gpl20.
- One of the Abs in the combination is specific for the V3 loop of HIV-1 envelope glycoprotein gpl20.
- the other is specific for the CD-4 binding site of HIV-1 envelope glycoprotein gpl20.
- the invention includes all Abs which are specific for epitopes within these epitope clusters which, when combined, are capable of synergistically neutralizing HIV-1 infection.
- the antibodies are human monoclonal antibodies, but the invention relates to other types of antibodies as well.
- the synergistic combination of human mAbs is preferably capable of achieving 95% neutralization of about 1 x 10 4 infectious units of the MN strain of HIV-l at a concentration of about 0.5 micrograms/ml.
- Preferred embodiments of the invention include the synergistic combinations of: human mAbs which competitively inhibit, in vitro, the binding of antibodies produced by the cell line 1125H to gpl20, and human mAbs which competitively inhibit, in vitro, the binding of antibodies produced by the cell line 4117C to gpl20, and which are capable of synergistically neutralizing HIV infection.
- the combination is capable of about 95% neutralization of about 1 x 10* infectious units of the MN strain of HIV-1 at a concentration of about 0.5 micrograms/ml.
- the antibody combination can be used for treatment or prevention of HIV infection.
- the antibodies are used together, but they may be administered sequentially.
- Also included in the invention is a cell line which produces human monoclonal antibodies specific for the V3 loop of HIV-envelope glycoprotein gpl20, which antibodies have the epitope specificity of those produced by the CP 1 line 4117C to gpl20.
- the present invention also relates to human monoclonal antibodies specific for a CD-4 binding site epitope of HIV-envelope glycoprotein gpl20 which is conserved among the IIIB, MN, SF-2, and RF HIV-1 strains.
- the antibodies are capable of neutralizing all of those strains and have high affinity for antigen.
- Cell lines producing those monoclonal antibodies, as well as related therapeutic and preventive uses, agents, methods of screening using the antibodies, vaccines, and assay kits are included in the invention as well.
- Figure 1 depicts electrophoretic patterns of mAbs 1125H, 2173C, and 2154B.1 reacting with gpl20 and gpl60 on 11% polyacrylamide gels in SDS.
- Figures 2A - 2C are graphs depicting competition ELISA using a gpl60 coated plate and a CD-4 inhibitor.
- Figure 3 is a graph depicting the neutralizing activity of mAb 1125H against the MN HIV-1 strain.
- Figure 4 depicts the apparent affinity of human mAbs 1125H, 2173C, 2154B.1, and 4117C.
- Figure 5 depicts a hypothetical binding scenario for the 1125H and 4117C antibodies.
- Figure 6 depicts the synergistic neutralization of the MN strain by human mAbs 1125H and 4117C.
- Figure 7 depicts the synergistic neutralization of the SF-2 strain by human mAbs 1125H and 4117C.
- Figures 8a and 8b depict combination index values calculated from experimental curves shown in Figures 6 and 7.
- Figure 9 depicts results of an experiment measuring the effect of 1125H on binding of 4117C to gpl60 MN and visa versa.
- Figure 10 depicts the synergistic neutralization of the MN strain by human mAbs 5145A and 4117C.
- Figure 11 depicts the synergistic neutralization of the SF-2 strain by human mAbs 5145A and 4117C.
- Figure 12 depicts the synergistic neutralization of the Illb strain by chimp anti- V3 Abs and 1125H.
- these particular mAbs of the invention are of human origin means that they have distinct advantages for use as an anti-viral drug in humans. These reagents possess a number of advantages over rodent MAbs for this purpose, including increased stability and very low immunogenicity in humans. Thus, human MAbs are much less likely to create deleterious anti-immunoglobulin responses than are mAbs from other species such as rodents, and it should be possible to obtain stable levels of therapeutic doses of human mAbs in humans.
- the invention includes the use of polyclonal antibodies against the CD-4 binding site and V3 regions, as well as the use of human mAbs against these regions. We have demonstrated that chimp polyclonal antibodies against the V3 region also synergize in this manner.
- mAbs instead of total serum antibodies for immunotherapy, however, is that the monoclonal antibody technology allows us to produce unlimited amounts of homogeneous reagents.
- the reagents may be further characterized and studied in detail and used as drugs for passive immunotherapy or treatment of HIV (see further below) .
- Heterogeneous human serum Abs cannot be used for this purpose; they are available in limited quantities, are different in each individual, and are composed of complex mixtures of antibodies, including blocking and virus-enhancing antibodies.
- the immortalized cell lines of the invention also allow one to isolate all or a portion of the expressed genes coding for the human mAb.
- genes may be altered so as to produce a human mAb with even greater affinity for antigen and/or to change the isotype, idiotype, or effector functions of the human mAb.
- Expression systems have been developed to allow expression and secretion of genetically engineered human mAbs in mouse cells.
- the neutralizing human mAb(s) should be extremely potent, so that neutralizing concentrations can be attained in vivo following administration of milligram amounts of human mAb(s) .
- the invention includes combinations of human mAbs against the CD-4 binding site region and the V-3 loop region which synergistically neutralize HIV-1.
- human monoclonal antibodies against each of these epitope clusters which have been produced, for example by the methods described below, are screened.
- a given combination of a human monoclonal antibody against the CD-4 binding site and a human monoclonal antibody against the V-3 region can be screened in a standard neutralization assay for synergistic neutralizing activity by comparing the individual neutralizing activity of each antibody, with the neutralization activity in an assay with the antibodies combined. Examples of such neutralization assays are described below.
- the ability of the antibody combination to synergize will be evidenced by a significant increase in neutralization activity over that obtained in the presence of equivalent concentrations of the individual antibodies.
- the extent of synergy can be quantitated by calculating the Combination Index using known statistical methods.
- a given anti CD-4 binding site human monoclonal antibody can be screened for a significantly increased neutralization activity in combination with the 4117C antibody.
- a given anti V-3 human monoclonal antibody can be screened for synergistic activity by combining it with the 1125H antibody and testing neutralization activity in the same manner.
- Another manner in which to obtain the synergistic antibodies of the invention is to screen human monoclonal antibodies against the CD- 4 binding site region which competitively inhibit the binding of 1125H to gpl20 in vitro, in combination with either 4117C, or antibodies which competitively inhibit the binding of 4117C to gpl20 in vitro.
- the antibodies employed in the combination of the invention are directed against the same epitope clusters as 1125H and 4117H.
- human monoclonal antibodies against other epitopes within these specific epitope clusters i.e. the CD-4 binding site epitope cluster and V-3 loop cluster, also synergistically react.
- synergistic values within the scope of the invention are, for example, those demonstrated for the results shown in figures 6 and 7. Similarly, combination index values obtained for those results demonstrate significant synergism within the scope of the invention. Combination index values as a a measure of synergism are further discussed below.
- the synergistic combination of human mAbs achieves 95% neutralization of about 1 x 10* infectious units of the MN strain of HIV-1 at a concentration of about 0.5 micrograms/ml.
- one of the human mAbs which competitively inhibits the in vitro binding of antibodies produced by the cell line 1125H to gpl20 combines synergistically in neutralizing HIV-1 with other human mAbs competitively inhibit the in vitro binding of antibodies produced by the cell line 4117C to gpl20.
- In vitro competitive binding assays are well known in the art.
- Another embodiment of the invention includes a combinati - of human mAbs wherein one of the human mAbs substantially has the epitope specificity of antibodies produced by the cell line 1125H and the other human mAbs substantially have the epitope specificity of antibodies produced by the cell line 4117C. Means of determining epitope specificity are also well known in the art.
- one of the human mAbs has the identifying characteristics of those obtained from the cell line 1125H and the other has the identifying characteristics of those obtained from the cell line 4117C.
- transformed cell lines which produce human monoclonal antibodies which have the epitope specificity of those antibodies produced by the cell line 4117C.
- Human monoclonal antibodies having these specificities are also included in the invention.
- polyclonal antibodies from different sources may be employed, in addition to the human antibodies we have described. Methods have been described in the literature for inducing neutralizing antibodies against different epitopes of HIV gpl20 in both rodents and chimpanzees. Antibodies against the V3 loop have been induced in both rodents (Javaherian et al, 1990) and chimps (Girard et al., 1991) by immunizing animals with synthetic V3 peptides either in free form, or conjugated to KLH. Anti-V3 antibodies have also been induced by immunizing chimps with purified gpl20 and gpl60 (Berman et al., 1990).
- Antibodies against both regions can also be produced in chimpanzees which have been infected with HIV, although the V3 region is immunodominan , and anti-V3 antibodies will predominate over anti-CD- 4 binding site antibodies.
- Monoclonal antibodies against these gpl20 epitopes can be prepared from immunized mice by standard techniques, and monoclonal antibodies can be prepared from chimps by following the EBV-transformation procedure described herein for human cells.
- Specific antibodies against both the V3 region and against the CD-4-binding site can be purified by immunoaffinity chromatography.
- AH-Sepharose beads are activated by treatment with glutaraldehyde, and conjugated to either purified V3 peptide or purified gpl20.
- Antibodies against V3 can be obtained by passing 10-fold diluted hyperimmune serum through the columns to allow the antibodies to bind, and washing off unbound antibodies with saline and 0.5M NaCl solutions.
- V3-specific antibodies can be eluted from the V3 column by washing with tris-glycine buffer, pH2.7 while V3 specific antibodies can be eluted form the gpl20 column by passing through excess V3 peptide.
- Antibodies against the CD-4-binding site can be eluted from the gpl20 column with tris- glycine buffer, and then purified by passing over a second gpl20-affinity column in which the CD-4- binding site had been blocked with excess soluble CD-4. Under these conditions, the anti-CD-4 binding site antibodies will not bind to the column and will be found in the flow-through, while all other antibodies will be retained. Following is a description of how human monoclonal antibodies to CD-4 binding site and to the V-3 loop can be obtained.
- Peripheral blood from HIV-1-seropositive individuals was used to establish transformed clonal human B cell lines which synthesize high affinity human mAbs against HIV-1 envelope proteins.
- the HIV-1-seropositive donors had normal white blood cell counts and no history of opportunistic infections.
- Human mAbs obtained against the CD-4 binding sit ⁇ " ere found which are specific for divergent strains of HIV-1, including the IIIB, MN, SF-2 and RF strains.
- Three cell lines obtained which produce mAbs having this capability are referred to herein as 2173C, 2154B.1 and 1125H. These have been deposited at the ATCC and assigned accession nos. CRL10580, CRL10581, and CRL10582 respectively.
- mAb against the V-3 region 4117C, which reacts with less strain specificity than prior human antibodies against V- 3.
- This mAb is specific for a variety of strains, including MN, SF-2 and other strains described below. It has been deposited at the ATCC and assigned accession no. CRL10770. These cultures have been deposited to exemplify the invention, but procedures are described in detail below to allow one skilled in the art to obtain such materials.
- MAbs from the deposited cell lines can be used to aid in screening to identify cell lines producing mAbs specific for the same, or nearby, epitopes. Using procedures described in detail below, cell lines expressing these mAbs are obtained.
- neutralizing where not otherwise defined, is used herein to mean the ability of antibodies, at a concentration no greater than approximately lOO ⁇ g/ml, to reduce in vitro infection of H9 cells by at least 90% (compared to control cultures to which no antibody is added) by HIV-1 in the range of 10 4 - 10 5 total infectious units as assessed by the overnight neutralization assay described below.
- Peripheral blood mononuclear cells from HIV infected individuals were immortalized by transformation with Epstein-Barr virus using a modification described below of the p-. cedure of Gorny et al. (Gorny et al. 1989) .
- the an i-CD-4 binding site humAb cultures were obtained by screening immortalized cultures for production of anti-env antibody using recombinant gpl60 coated ELISA plates.
- Our use of recombinantly produced gpl60 in screening differs from other researchers, who have used for example, HIV-l lysate (Gorny et al. 1989) , fixed HIV-1-infected cells (Robinson et al.
- gpl60 which is obtained from higher eukaryotic transformed hosts.
- gpl60 expressed by transformed baby hamster kidney cells as per Kieny et al. (Kieny et al. 1988) This version of gpl60, supplied by Pasteur Merieux, lacks the site which is normally cleaved to form gpi20 and gp41.
- this cleavage site is not believed to have any effect on the screening process and to be distant from the epitope[s] which the antibodies of this invention are specific for.
- Alternative preferred sources include gpl60 or gpl20 obtained from other transformed higher eukaryotic hosts.
- gpl60 or gpl20 obtained from other transformed higher eukaryotic hosts.
- recombinant gpl20 per Leonard et al. (Leonard et al. 1990) available through the AIDS Research and Reference Reagent Program (NIH) are also believed effective in screening cultures for mAbs of the invention.
- Competitive ELISAs, testing for competitive inhibition with CD-4 can be performed in order to further screen for cultures producing anti-CD-4 binding site huMabs.
- Immunofluorescence and neutralization assays may be conducted in order to positively identify those antiCD-4 binding site cultures which are specific for the epitope which affords broad neutralizing activity across the four strains: IIIB, MN, SF-2 and RF, among others.
- peptides which present the hvl-V3 loop and peptides which present gp41 epitopes can be used as negative controls to establish the specificity of mAbs for the epitope[s] defined by the anti-CD-4 binding site mAbs of this invention. These peptides are described in greater detail below.
- Further screening to determine whether cultures are producing mAbs to the same epitope cluster as one of the antibodies of the invention can be done with a competitive ELISA assay using any of the three anti CD-4 binding site antibodies or anti V3 mAbs which we have deposited. Such an assay would determine if mAbs from the culture being screened compete with those described herein in binding to an epitope presented on, for example, recombinant gpl60 coated ELISA plates.
- MAbs which compete would be specific for the same or adjacent epitopes.
- a suitable competitive assay is described below.
- the deposited anti-CD-4 binding site mAbs of this invention do not react with LAV-2.
- Each of these types of mAbs from our deposited cell lines reacted with both acetone and methanol-fixed HIV- 1 infected cells. Furthermore, each also reacted with formaldehyde-fixed HIV-1 infected cells, a result obtained in our hands only when the epitope recognized is expressed on the infected cells' surface.
- NYNKRKRIHIGPGRAFYTTKNIIGC described in Gurgo et al. 1988. 4117C may be characterized by its reactivity with the V3 peptide of the following strains: MN, SF-2, NY-5, CD-451, WMJ-1, WMJ-3, Z- 3, Z-321, and SC; and by its lack of reactivity with the following strains: WMJ-2, LAV-MA, BR, LAV-IIIB, PV-22, ELI, Z-6, NX3-3, JY-1, HXB-2 and MAL.
- competition assays with the deposited antibody 4117C may be carried out to further screen for related antibodies. Examination of the reactivity of antibodies against specific peptides can be used to determine the strain specificity of the screened antibodies.
- the neutralization abilities of the antibodies deposited have been determined, as described below. It should be appreciated that we used greater amounts of virus in the overnight neutralization assay than other investigators do in their neutralization assays that typically require as long as a week to detect viral infection of control cultures (i.e., those with no antibody added) (Ho et al. 1987) . Therefore, larger amounts of mAb are required to effect a given level of neutralization in our assay than in those assays in which many-fold less virus is added. To compare the efficacy of neutralization by our mAbs with those of other mAbs whose neutralization activity is determined by several- day assays, it is necessary to compare the input number of tissue culture infectious units of virus utilized in the different studies.
- the 4117C mAb has approximately equal ability to neutralize to MN strain as does 1125H, and appears to neutralize SF-2 even better. These findings are particularly significant as MN and SF-2 are two of the most commonly represented strains in the United States.
- Figure 4 shows the apparent affinity constants of human anti-gp 120 mAbs from the four deposited cell lines described. Antibodies with K-values in the vicinity of 10 9 L/Mole (Berzofsky et al. 1989) are considered to be of high affinity. By this standard, all four human mAbs possess high affinity for gp 120.
- Antibody 4117C shows diminished reactivity with reduced gpl20, as compared with unreduced gpl20, but not complete loss of activity.
- Isotype characterization of the four mAbs of our deposited cell lines was determined by using a variation of the immunofluorescence assay for heavy chain analysis and a variation of ELISA for light chain analysis.
- the heavy chain isotypes, as determined by immunofluorescence assay, was found to be IgGl.
- the light chain isotype of the CD-4 binding site antibodies was determined to be Kappa whereas that of the 4117C was determined to be lambda. The procedures are described below.
- the mAbs of the present invention can be used therapeutically to treat HIV-1 infected individuals. They may be administered by themselves or in conjunction with other anti ⁇ viral therapies, such as AZT or DDI, in order to slow the progress of HIV-1 induced disease.
- anti ⁇ viral therapies such as AZT or DDI
- the synergistic combination which we have discovered is most exciting in this regard as much less of these antibodies is required in order to neutralize HIV. They provide a distinct advantage over the single human antibodies which have been described.
- combinations of purified HuMAbs, mixed in appropriate ratios can be adjusted to 5% solution in sterile saline, yielding a concentration of 50 mg/ml. The best ratio of the synergizing antibodies is determined experimentally, using the 24 hour fluorescent focus assay described below.
- equipotent concentrations of the two antibodies 1125H and 4117C can be used; i.e. a concentration of each which has been determined to give comparable levels of neutralization to each other.
- the amount of this solution required for protection can be determined in animal experiments, performed first in Hu-SCID mice (Mosier et al. 1988, McCunc. et al. 1988) and subsequently in chimpanzees.
- the therapeutic reagent can consist of as few as two synergizing antibodies, although it is believed that the most efficient composition will contain a larger number of different antibodies directed against the two major antigenic sites.
- Passive administration of human mAbs of the invention may also be used to prevent HIV-1 infection in cases of acute exposure to HIV.
- studies indicate (Devash et al. 1990) a striking correlation between the presence of high affinity serum Abs against the hvl-V3 region of the MN strain in human neonates born to HIV-1 seropositive mothers and the absence of HIV-1 infection in the neonates. Therefore, it can be concluded that the HIV-1 seropositive mother transfers high affinity anti-hvl-v3 antibodies to her fetus, and the fetus is thus protected from HIV-l that it may receive from the mother at the time of birth.
- the results of Devash are evidence that high affinity neutralizing Ab against HIV-l can protect the fetus from HIV-l infection when present at the time of viral challenge.
- the HIV-l neutralizing mAbs of this invention could be passively administered to pregnant seropositive women to prevent their fetuses from becoming HIV-l infected.
- these combinations of mAbs may be used to prevent HIV-l infection by administering them to individuals near the time of their exposure to HIV-l.
- Properties of the preferred mAbs of this invention which make them excellent even by themselves for these applications are: 1) their demonstrated HIV-l neutralizing activity in vitro at low mAb concentrations, 2) their broad HIV-l strain specificity, 3) their high affinity for antigen (HIV-l gp 120) , 4) the fact that they are of human origin and will, therefore, elicit few, if any, deleterious immune reactions whtn administered to humans, and 5) the heavy chain isotype of the mAbs is IgGl, which is significant because human IgGAbs are the only class of Ab able to cross the placenta, and Abs of the IgGl subclass can potentially kill HIV-1-infected cells in vivo via Ab- and complement-dependent cytotoxicity (ACC) and/or Ab-dependent cellular cytotoxicity (ADCC) (see further below) .
- ACC
- the mAbs of this invention by themselves can be used to prevent HIV-l infection, the mAbs may be modified to enhance their in vivo anti-viral activity by covalent attachment of a toxin such as ricin A or pokeweed antiviral protein to the mAbs. It has been demonstrated that such anti-HIV-1 mAbs-toxins (immunotoxins) are capable of specifically killing HIV-l infected cells in vitro.
- a toxin such as ricin A or pokeweed antiviral protein
- the anti CD-4 binding site mAbs of this invention can also be used to prepare a vaccine to confer immunity to HIV-l. They may be used to identify the epitope for which they are specific (see below) . Peptides containing that epitope may then be synthesized chemically, using standard Merrifield synthesis techniques, or synthesized by recombinant DNA techniques known in the art. If prepared by recombinant DNA techniques it may be preferred that a higher eukaryotic host be used in order to more closely duplicate glycosylation patterns of the native protein. For example, techniques for recombinant DNA-based synthesis of gpl20 peptides in CHO cells is described by Lasky et al. (Lasky et al. 1986.
- unglycosylated molecules may be as or more effective than glycosylated molecules; these may be produced by expression of gpl20 peptides from recombinant DNA constructs in bacteria (for example, see Putney et al. 1986) .
- peptides are chemically synthesized and/or expressed by cells, it is likely that disulfide bonds must be formed between the peptides in order to recreate the epitope (or a similar structure) to be recognized by our anti- CD-4 binding site mAbs. If the peptides are chemically synthesized, disulfide bonds can be formed between the peptides by controlled oxidation following peptide synthesis, whereas peptides expressed in cells are likely to form such bonds between cysteine residues in vivo . In either case, we anticipate that only a fraction of the total molecular species formed would result in a structurefs] recognized by our mAbs.
- the synthetic or expressed mixture of peptide-derived structures can be passed over an affinity column comprised of covalently bound mAbs in order to identify any molecular species that are recognized by the mAbs.
- the entire mixture of peptide-derived structures could be previously radiolabeled in order to determine what percentage of the total mixture is recognized by the mAbs.
- the bound peptide derived structures(s) can be further characterized by tryptic mapping using HPLC (Leonard et al. 1990) in conjunction with sequencing and amino acid composition analyses. This approach allows one to define the minimal structural requirements of a synthetic and/or recombinant gpl20 fragment that are required for recognition of that fragment by our mAbs..
- gpl20 peptide-derived structures can be created once a larger synthetic structure has been defined as a well-recognized epitope (or epitope mimicker) for our mAbs.
- An alternate method of preparing a vaccine would be to purify chemically (Lasky et al. 1987) or proteolytically fragmented gpl60 on a column having the mAbs of the invention bound thereto. Mixtures of fragments can be obtained which are enriched in the epitope for which the mAbs of the invention are specific. These mixtures, after testing for effectiveness as described above, can be used for immunization. Individual fragments from the mixture may also be isolated and used.
- the epitope may be tested for efficacy in rodents and chimpanzees.
- the epitope is presented either alone or covalently attached to a carrier, such as keyhole limpit hemocyanin (KLH) , to enhance its immunogenicity.
- a carrier such as keyhole limpit hemocyanin (KLH)
- Adjuvants such as aluminum hydroxide are also included with the epitope to enhance the immune response.
- Animals' sera can be tested for the development of broadly neutralizing antibodies, i.e. antibodies capable of neutralizing diverse strains of HIV-l. In the case of chimpanzees, those animals developing such antibodies would then be challenged with different strains of HIV-l and their level of anti-viral protection assessed.
- hvl-V3 region For vaccination purposes, it may therefore be preferable to remove the hvl-V3 region, and possibly other regions, from gpl20 or gpl60 in order to obtain a broadly neutralizing Ab response against the epitope(s) recognized by the anti CD- 4 mAbs of this invention.
- peptides synthesized as described above can be engineered using known techniques to delete the hvl-v3 region.
- mixtures of fragments obtained can be further purified to remove fragments containing the hvl-v3 region using known techniques.
- a vaccine which effectively presents the epitope for which the antibodies of the invention are specific and elicits broad neutralizing ability against HIV-l strains including IIIB, SF2, MN and RF is not known in the art.
- Such a vaccine would not predominantly produce antibodies against hvl-v3, as we believe ordinarily happens when, for example, whole recombinant gpl20 or gpl60 is used to immunize.
- By “effectively presents” we mean that the antigen, when used to immunize an uninfected individual, elicits production of antibodies which neutralize the IIIB, SF-2, MN and RF strains, either upon challenge to the individual with those strains or as determined in in-vitro testing.
- the invention includes a vaccine which incorporates an antigen which consists of an epitope for which the anti CD-4 binding site antibodies of the ivention are specific.
- the antigen is capable of eliciting an immune response consists essentially of the production of antibodies which have the epitope specificity of the antibodies of the invention.
- the homologous epitope from HIV-2 can be synthesized in order to create a vaccine against HIV-2.
- the HIV-2 gpl20 sequence is known, and the cysteine residues (which form disulfide bonds) are relatively well conserved between HIV-l and HIV-2 sequences, particularly in the regions around the CD-4 binding site (Myers et al. 1989) .
- a vaccine against HIV-2 can be obtained based on the analogous HIV-2 structure to the epitope of HIV-l which we can identify with our mAbs.
- Another application of the anti CD-4 mAbs in this invention is their use in a competitive immunoassay (see further below) to study the natural human antibody response to the HIV-l epitopes recognized by the mAbs.
- This type of assay allows research as to : 1) What proportion of HIV-l-infected individuals develop Ab against this epitope[s]? 2) How long after HIV-1- infection and/or at what stage of HIV-1-induced disease does Ab against particular epitopes appear? 3) Do individuals with high titers of Ab against the epitopes have a better prognosis than those without such Ab? 4) Do mothers with Ab against the epitopes transmit HIV-l to their fetus less frequently than those mothers without Ab against this epitope?
- the present invention also includes test kits to measure th ⁇ r resence of human Abs against the epitopes of th-_ nti CD-4 mAbs claimed in this application.
- the kits contain human monoclonal antibodies having the specificity described above, a solid phase on which is coated an antigen which the monoclonal antibodies are specific for, and means for detecting the formation of a complex between the monoclonal antibodies and the antigen.
- a competitive ELISA using biotin labeled human mAbs can be performed similarly to the competitive inhibition assay described below. Such an assay determines whether the sample has any antibody competing with the antibody of the invention.
- An assay for determining the presence of the antigen which the mAbs of the invention bind to can also be performed using, for example, a sandwich format wherein a solid phase is coated with antibody to HIV envelope, the sample is added, and then biotin labeled mAb of the invention is added. Following a wash, enzyme labeled avidin would then be added as well as enzyme substrate. Such general types of assays are well known in the art.
- the invention also includes kits for determining an antigen for which the anti CD-4 mAbs of the invention are specific.
- such a kit may comprise the anti CD-4 mAbs of the invention, a solid phase on which is coated an antibody specific for HIV-l env, and means for detecting the formation of a complex among the mAbs of the invention, the antibody specific for HIV-l env, and an HIV antigen for which the mAbs are specific.
- sandwich type immunoassay is well known to one skilled in the art.
- Gram quantities of this invention's mAbs are preferably obtained in order to administer efficacious amounts of these . ⁇ agents to humans in-vivo . These amounts coul ' be obtained by growth of our human cell lines in a ini- bioreactor. Additionally, cost-effective methods to increase human mAb production are: 1) fusion of our EBV-transformed lines with a human/mouse heteromyeloma (Teng et al. 1983; Kazbor et al. 1982) and 2) PCR amplification of expressed i munoglobulin V H and V L genes from human cell lines using published human primer sequences (Larrick et al.
- the invention also includes moieties having the same function as monoclonal antibodies, such as Fab fragments, F(ab') 2 , Fd or other fragments, modified proteins such as chimeras with altered Fc regions, or having mutagenized idiotypic regions, so long as they bind to the same epitope as the human monoclonal antibodies of the invention. Techniques for producing such fragments or modified antibodies are known to one skilled in the art (Parham 1986) .
- the preferred therapeutic reagent of this invention consists of mixtures of engineered antibodies of different isotypes, including IgGs, IgMs, and IgAs, in order to increase the affinities and effector activities of the antibodies.
- Peripheral blood from HIV-l seropositive individuals who are hemophiliacs was obtained. These individuals were classified as Walter Reed 5 Stage 2A, i.e., they had normal white blood cell counts and no history of opportunistic infections.
- RPMI 1640 medium 15 RPMI 1640 medium.
- the cells were spun down (400 x g, 20 min.), and then resuspended in 50 ml of RPMI 1640 medium, counted, and spun down again as before. Cells were then resuspended at a density of 2 x 10 6 cells/ml in RPMI 1640 medium
- EBV Epstein-Barr virus
- DNA was isolated from the four identified cell lines followed by restriction enzyme digestion, agarose gel electrophoresis, blotting to nitrocellulose, and hybridization to 3z P-labeled nick-translated probe. (Eckhardt et al. 1982) .
- the DNA was cut with Hind III, which allows visualization of rearrangements due to V-D-J joining upon hybridization with an immunoglobulin J H region probe (Ravetch et al. 1981) .
- the J H probe used was a EcoRI-Hindlll fragment approximately 3.3 kilobases in length from the germ line J H locus; the Hindlll site at its 3' end is present in the germ line DNA [Ravetch, J. V., U. Siebenlist, S. Korsmeyer, T. Waldmann, and P. Leder. (1981) Cell 27:583-591], whereas the EcoRI site at its 5' end was created upon cloning. The monoclonality of the four cell lines was confirmed.
- ELISA assays were used to detect HIV env- specific Abs.
- the initial screening of EBV- transformed human cultures for production of anti- env Ab was done using either recombinant gpl60 (Kieny et al.) or V3 MN peptide to coat PVC ELISA plates (Flow/ICN) .
- gpl60 Kieny et al.
- V3 MN peptide V3 MN peptide to coat PVC ELISA plates
- a variety of other HIV proteins or peptides can be used to determine the specificity of the human mAbs. These include recombinant gpl20 of the IIIB strain produced by Celltech, Inc. and available through the AIDS Research and Reference Reagent Program (NIH) or described by (Leonard et al.
- V3 peptides from a variety of strains (strain specificity is described above) ; or pl21, a gp41 peptide (amino acids 565-646) sold commercially by Dupont or described in Chang, et al., European Patent Application 0199438 published October 29, 1986. 4117C is negative for gpl20 of the IIIB strain and for pl21. 1125H is negative for the V3 peptides, and for the gp41 peptide as well. Unless noted otherwise, 50 ng/well of protein diluted in Na 2 C0 3 /NaHC0 3 buffer, pH 9.8 was incubated in the plates overnight at 4°C.
- the plate was washed 3 times with PBS/tweenyazide (Sigma® PBS with 0.05% Tween 20, 1 mM NaN 3 ) .
- PBS/tweenyazide Sigma® PBS with 0.05% Tween 20, 1 mM NaN 3
- the wells of the plate were blocked (to prevent nonspecific binding) by incubation with 50 ⁇ l of 2% BSA in PBS for 1.5 hr., 37° C.
- 50 ⁇ l of supernatant from human cell lines was added to the wells and incubated for 1.5 hr., 37 C C. Unbound Ab was washed from the wells, and 50 ⁇ l of a 1/500 dilution of goat anti-human IgG conjugated to alkaline phosphatase (Zymed®) in 2% BSA was added to each well.
- alkaline phosphatase substrate sodium p-nitrophenyl phosphate
- diethanolamine buffer 1M diethanolamine, 0.5mM MgCl 2 , 3mM NaN 3 , pH 9.8
- the absorbance at 405nm was read in a Titertek Multiskan Plus® ELISA reader (Flow®) at times ranging from 5 min. to 2 hr. following substrate addition.
- the background obtained when culture media was used rather than supernatant from human cell lines was automatically subtracted from the results by the ELISA reader.
- glycoproteins in HIV-1-infected cells at 5-7 x 10 s cells/ml were labeled with 3 H-glucosamine (lOO ⁇ Ci/ml) as described (Pinter et al. 1989) .
- the cells were then lysed and immunoprecipitated as previously described (Pinter et al. 1988) . Briefly, the cell pellet was brought up in lysis buffer at a concentration of 5 x 10 6 cells per ml.
- the lysate was then precleared with fixed, killed staphylococcus aureus cells (Staph A) , and 70 ⁇ l of pre-cleared lysate was added to 70 ⁇ l of supernatant from human Ab-producing cell lines or 1/400 dilution of human sera. Following an incubation and precipitation by Staph A, the pellet was brought up in Laemmli sample buffer containing 1% DTT and run on an 11% polyacrylamide gel as described (Laemmli 1970) . Fluorography (Bonner et al 1974) then allowed detection of radiolabeled, immunoprecipitated glycoproteins in 5 the gel.
- HIV-l strains IIIB Popovic et al. 1984; Ratner et al. 1985
- SF2 Levy et al. 1984;
- strains IIIB, MN, and RF were confirmed by us using strain-specific antisera against the hypervariable V3 loop (hvl-v3) of each strain in an immunofluorescence assay.
- the slides were then washed 2X in 100-200 ml PBS, using a slide-holder and trays.
- formaldehyde fixation 0.5% formaldehyde in PBS containing lOmM NaN 3 was then added to each well of the slides and incubated with the immobilized cells for 30 min. at room temperature.
- the slides were then washed IX in distilled H 2 0 as discussed above and allowed to dry.
- acetone or methanol fixation following the 2 washes in PBS discussed above, the slides were washed IX in distilled water and then incubated in 100-200 ml of acetone or methanol for 8 mins. The slides were then removed from the fixative and allowed to air dry.
- Heavy chain subclass was determined using a variation of the immunofluorescence assay. Human mAb-producing cells were attached to slides and fixed with acetone. The slides were blocked with 25 bovine gamma globulin and washed as discussed above. Next, a 1/5000 dilution of human IgG subclass-specific mouse monoclonal Ab (Zymed) (specifically, anti-IgGl and anti-IgG2 were used in these experiments) was added and incubated for
- Light chain isotype was determined by a variation of the ELISA assay discussed above. Following incubation of supernatant from mAb- producing human cells with gpl60 in duplicate ELISA wells, the mAb isotype was determined by development of one well with goat anti-human kappa Ab conjugated to alkaline phosphatase and the other well with goat anti-human lambda Ab conjugated to alkaline phosphatase. Both of the latter reagents (Tago) were used at 1/3250 dilution.
- the human mAbs Prior to conducting neutralization assays, the human mAbs were purified on recombinant protein A Sepharose columns essentially as described (Harlow et al. 1988) .
- the column fractions containing mAb (as determined by ELISA assay of fraction aliquots) were concentrated in an AMICON centriprep 30 column and dialyzed against PBS.
- An irrelevant mAb of the IgG2 subclass was purified in the same manner from the 1A2 cell line (Siadek et al. 1985), which was derived from the GM1500 cell line (Dolby et al. 1980) .
- the purified 1A2 mAb was used as a negative control in neutralization and competitive inhibition experiments.
- the neutralization assay was carried out as follows. Purified Abs, or combinations of Abs, were diluted in complete media containing 10% FCS to obtain concentrations ranging from 0.1 to 20 ⁇ g/ml in a total volume of lOO ⁇ l. Included in this volume was approximately 10 4 -10 s tissue culture iv " 'tious units of HIV-l. After a 30 min. prein&l.oation of virus and mAb at room temperature, the mixtures were each added to 1 x 10 5 H9 cells in a final volume of 200 ⁇ l.
- the cells in each well were plated onto separate wells of poly L-lysine-coated slides and stained sequentially with a rat anti-nef serum (1/200) followed by a rabbit anti-rat IgG Ab conjugated to FITC (1/50) (Zymed) .
- the latter two antibodies were diluted in 1 mg/ml bovine gamma globulin in PBS.
- the cells were counterstained with Evan's Blue, and the percentage of infected cells from each culture relative to the control (no mAb added) was assessed by counting immunofluorescent cells versus total counterstained cells under the fluorescence microscope.
- lysates were immunoprecipitated with: a 1/400 dilution of human serum from an HIV- 1 seropositive individual (lanes 1 & 6); 0.7 ⁇ g purified 1125H mAb (lanes 2 & 7) ; undiluted supernatant from 1125H (lanes 3 & 8) , 2154B.1 (lanes 4 & 9) , and 2173C (lanes 5 & 10) cells. The latter three supernatants contained approximately 1-3 ⁇ g mAb/ml. Results with t s "uman serum (lane 1, positive control) show that ' : ..e expected IIIB strain glycoproteins, gpl60 iPr t .
- v precursor envelope protein
- gpl20 S_7,- v , surface envelope protein
- gp41 iTM. nv transmembrane envelope protein
- the corresponding glycoproteins of the RF strain each migrate at a lower apparent molecular weight than their counterparts from the IIIB strain (lane 1) . This must be due to glycosylation differences in the RF and IIIB strain glycoproteins, since there is no significant difference in the number of amino acids in these molecules between RF and IIIB strains (Starcich et al. 1986) .
- strain specificity of the 1125H, 2173C, 2154B.1 and 4117C mAbs was test. d by immunofluorescence assay usi ..--. __ixed cells 15 infected with one of several HIV strains.
- the anti-CD-4 mAbs were reactive with the IIIB, MN, SF-2 and RF HIV-l strains, as well as with one (JRCSF) of two primary HIV isolates tested. None of these mAbs reacted with LAV-2, an 20 HIV-2 isolate. Each of the three mAbs reacted with both acetone- and methanol-fixed HIV-infected cells. Furthermore, each of the mAbs reacted with formaldehyde-fixed HIV-1-infected cells, a result obtained in applicant's hands only when the 25 epitope recognized by the mAb is expressed at the cell surface. Each of the mAbs also reacted with live, HIV-1-infected cells.
- the 4117 mAb was reactive with the MN, SF-2, * and the JRCSF primary isolate, as well as with two
- FIG. 2A the open squares represent supernatant from 50- 69, an anti-gp41 human mAb (Gorny et al. 1989) .
- the closed diamonds in figure 2A represent supernatant from 1125H.
- Figure 2B shows results for supernatant from 2173C.
- Figure 2C shows results for supernatant from 2154B.1.
- ""..e results show that the binding of the 50-69 (co....rol mAb) to gpl60 is not inhibited by soluble CD-4, whereas that of the other three mAbs (1125H, 2173C, 2154B.1) is inhibited by soluble CD-4 in a concentration-dependent fashion.
- the affinity of mAbs for gpl60 or V3 driving N was determined by diluting mAbs of known concentration and assaying the various dilutions on gpl60 or V3tone N coated plates by ELISA as discussed above. It has been demonstrated that the concentration at which half-maximal Ab binding is observed is a rough value of 1/K (van Heyningen et al. 1987) .
- 2173C, 2154B.1 and 4117C mAbs was determined to be IgGl.
- the light chain isotype of each of the three antiCD-4 binding site mAbs was determined to be kappa whereas that of 4117C was found to be lambda.
- a competition assay can be performed in order to screen culture supernatants or human serum for antibody against the epitopes, or epitope clusters, which the mAbs of the invention are specific for.
- the competition assay is carried out essentially as described above for the competition assay with CD-4.
- biotin- labeled mAbs from cell line 1125H, 2173C, 2154B.1 or 4117C are used in competition with supernatant from the culture screened to bind to gpl60 or V3lock N
- 4117C was found to recognize a variety of divergent HIV strains, including MN, SF-2, FV (New York) , 11699 (Central Africa) , and the JR-CSF primary isolate (Los Angeles) (Koyanagi et al. 1987) . 4117C human mAb is less strain specific
- Fig. 6 shows that an equimolar mixture of the two human mAbs neutralizes the MN strain of HIV significantly better than either of the two human mAbs alone.
- the mixture of human mAbs effects 50% neutralization of virus at approximately a 5 fold lower concentration than that of either human mAb alone, meaning that each of the individual human mAbs is 10 fold more effective when mixed with the other human mAb than when used alone. This is a dose reduction index of 10 for each of the human mAbs at the 50% neutralization level.
- CI values are assigned based on the combination index (CI) values calculated from experimental curves such as those shown in Figs. 6 and 7. CI values less than 1 indicate synergy (Chou and
- Fig. 8 shows the CI plots calculated from our experimental results (Figs. 6 and 7) .
- one of the human mAbs was tagged with biotin, and mixed with different amounts of the second, unlabeled antibody. Bound biotinylated antibodies were then detected by the binding of streptavidin in an ELISA assay. The antigen used
- Cell line 5145A was derived by the same protocol as 1125H.
- the 5145A HuMAb has the following characteristics. Its binding to gpl60 is inhibited by soluble CD-4 similarly to that of 1125H, and its epitope is destroyed by reduction, also similar to that of 1125H. Its apparent affinity constant is 1 x 10 9 L/mole. It is an IgG HuMAb; its IgG subclass remains to be determined. Its light chain is of the kappa isotype. Like 1125H, 5145A reacts with MN-, IIIB- and RF- infected cells by immunofluorescence.
- 5145A recognizes a different epitope of the CD-4 binding site than 1125H based on its neutralization of the 4 HIV-l strains mentioned above. Specifically, 1125H neutralizes the IIIB, SF-2, and MN strains significantly better than the RF and SF-2 strains, whereas the 5145A HuMAb exhibits virtually identical neutralization of the 4 strains discussed and at levels comparable to the 1125H HuMAb's neutralization of the MN strain (see Fig. 6) . This difference in pattern of strain neutralization must be due to a difference in epitope specificity of the 5145A and 1125H HuMAbs, since posses comparable affinity for gpl20.
- HuMAbs 5145A anti-CD binding site
- 4117C anti-V3
- Chimpanzee #499 was immunized with V3 peptide as described in Girard et al. 1991 (PNAS paper) and serum taken at the peak of neutralizing Ab titer (also shown in op. cit.).
- the anti-V3 Abs were purified on an affinity column with V3 peptide of IIIB strain attached as described below.
- the chimpanzee Ab concentration was determined as described for the HuMAbs, except that the IgM, IgA, and IgG concentrations were determined in separate assays with purified human Ab standards of each isotope.
- the total chimpanzee anti-V3 Ab concentration was taken to be the sum of the concentrations of these three antibody classes.
- Figure 12 shows that chimp anti-V3 Abs and 1125H mixed at 1:1 molar ratio synergistically neutralize the Illb strain. This is significant not only because it shows that anti-V3 Abs against different epitopes can participate in synergistic neutralization (chimp anti-V3 and 4117C) , but also because it includes another HIV-l strain, i.e., IIIB, in our observations of synergistic p.- Vietnamese-alization.
- Lasky, L.A. Nakamura, G., Smith, D.H., Fennie, C. , Shimasaki, C. , Patzer, E. , Berman, P. Gregory, T. , and Capon, D.J. (1987). Delineation of a region of the human immunodeficiency virus type 1 gpl20 glycoprotein critical for interaction with the CD-4 receptor. Cell. 50, 975-985.
- Lasky, L.A. J.E. Groopman, C.W. Fennie, P.M.
- Lussenhop N.O., Goertz, R. , Wabuke-Bunoti, " ⁇ . , Gehrz, R., and Kara, B. (1988). Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology. 164, 362-372. Myers, G. , A. Rabson, S. Josephs, T. Smith, J.
- HIV-l human immunodeficiency virus type 1 glycoprotein gp41 enhance HIV-l infection in vitro. J. Virol. 64, 5301-5305.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4501832A JPH06502539A (en) | 1990-10-26 | 1991-10-25 | Neutralizing human monoclonal antibody specific for the V3 loop and CD-4 binding site of HIV-1 GP120 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60414690A | 1990-10-26 | 1990-10-26 | |
US604,146 | 1990-10-26 | ||
US71533691A | 1991-06-14 | 1991-06-14 | |
US715,336 | 1991-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992007878A1 true WO1992007878A1 (en) | 1992-05-14 |
Family
ID=27084597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/007910 WO1992007878A1 (en) | 1990-10-26 | 1991-10-25 | Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5922325A (en) |
EP (1) | EP0554401A4 (en) |
JP (1) | JPH06502539A (en) |
AU (1) | AU9072991A (en) |
CA (1) | CA2094713A1 (en) |
HU (1) | HUT66445A (en) |
WO (1) | WO1992007878A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0588750A2 (en) * | 1992-08-05 | 1994-03-23 | Centro De Ingenieria Genetica Y Biotecnologia | Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv |
WO1995024904A1 (en) * | 1994-03-16 | 1995-09-21 | Tanox Biosystems, Inc. | Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies |
AU684073B2 (en) * | 1993-02-24 | 1997-12-04 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
US5872222A (en) * | 1991-04-19 | 1999-02-16 | Tanox Biosystems, Inc. | Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants |
US6106835A (en) * | 1991-04-19 | 2000-08-22 | Tanox, Inc. | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators |
US6117982A (en) * | 1991-04-19 | 2000-09-12 | Tanox, Inc. | Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators |
US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
US6197298B1 (en) | 1991-04-19 | 2001-03-06 | Tanox, Inc. | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals |
US6420336B1 (en) | 1995-04-27 | 2002-07-16 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of using cyanovirins topically to inhibit viral infection |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US7339037B2 (en) | 2001-03-22 | 2008-03-04 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US7754420B2 (en) | 1995-04-27 | 2010-07-13 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of using cyanovirins to inhibit viral infection |
EP2230250A1 (en) * | 2007-11-19 | 2010-09-22 | Kumamoto University | Anti-hiv monoclonal antibody |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2784792A (en) * | 1991-10-15 | 1993-05-21 | New York University | Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv |
US7115262B1 (en) | 1999-03-16 | 2006-10-03 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric protein for prevention and treatment of HIV infection |
US20040063605A1 (en) * | 2000-08-02 | 2004-04-01 | Jesper Eugen-Olsen | Composition and method for the treatment or prevention of hiv infection |
AU2003299085B2 (en) * | 2002-09-27 | 2008-04-10 | Tanox, Inc. | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
US8603736B2 (en) | 2004-06-07 | 2013-12-10 | Monogram Biosciences, Inc. | Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays |
EP1834183A1 (en) * | 2004-12-31 | 2007-09-19 | Genentech, Inc. | Detecting human antibodies in non-human serum |
US20090110690A1 (en) * | 2005-09-06 | 2009-04-30 | Kwong Peter D | Hiv Gp120 Crystal Structure and Its Use to Identify Immunogens |
CA2623197A1 (en) * | 2005-09-22 | 2007-03-29 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
WO2008134046A1 (en) | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
US4863730A (en) * | 1986-03-21 | 1989-09-05 | Cenfold Holdings, S.A. | Immunotherapy for AIDS patients |
US5087557A (en) * | 1986-06-23 | 1992-02-11 | Genetic Systems Corporation | Human monoclonal antibody to lymphadenopathy-associated virus |
US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
ATE151638T1 (en) * | 1987-02-20 | 1997-05-15 | Genentech Inc | METHODS AND PREPARATIONS FOR USE OF HIV ENV POLYPEPTIDES AND ANTIBODIES |
EP0295803B1 (en) * | 1987-05-29 | 1993-11-03 | Shuzo Matsushita | Monoclonal antibodies |
ATE122237T1 (en) * | 1987-05-29 | 1995-05-15 | Tanox Biosystems Inc | HIV-1 NEUTRALIZING MONOCLONAL ANTIBODIES. |
NL8702403A (en) * | 1987-10-09 | 1989-05-01 | Stichting Centr Diergeneeskund | OLIGOPEPTIDES AND THEIR USE FOR DIAGNOSTIC AND VACCINATION PURPOSES FOR AIDS AND ARC. |
US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
US5298419A (en) * | 1988-03-31 | 1994-03-29 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Human hybridomas and monoclonal antibodies which bind both gp41 and gp120 envelope proteins of human immunodeficiency virus |
JPH05506561A (en) * | 1989-06-05 | 1993-09-30 | レプリゲン・コーポレーション | HIV-1 MN gp120 human monoclonal antibody |
WO1991006575A1 (en) * | 1989-11-03 | 1991-05-16 | Repligen Corporation | Hiv-1 specific human monoclonal antibody |
WO1991009625A1 (en) * | 1989-12-21 | 1991-07-11 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes |
JPH05506142A (en) * | 1990-01-16 | 1993-09-16 | レプリゲン・コーポレーション | Monoclonal antibodies specific for non-immune dominant epitopes of HIV proteins |
AU647108B2 (en) * | 1990-04-03 | 1994-03-17 | Genentech Inc. | Methods and compositions for vaccination against HIV |
WO1991017764A1 (en) * | 1990-05-16 | 1991-11-28 | Dana Farber Cancer Institute | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding |
AP237A (en) * | 1990-05-29 | 1993-04-29 | Cedars Sinai Medical Center | Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use. |
CA2044741A1 (en) * | 1990-06-18 | 1991-12-19 | Jade Chin | Hiv gp120 monoclonal antibodies |
WO1993004693A1 (en) * | 1991-09-09 | 1993-03-18 | Repligen Corporation | Synergistic inhibition of hiv-1 |
AU2784792A (en) * | 1991-10-15 | 1993-05-21 | New York University | Human monoclonal antibodies to the cd4-binding domain of hiv, uses thereof and synergistic neutralization of hiv |
-
1991
- 1991-10-25 WO PCT/US1991/007910 patent/WO1992007878A1/en not_active Application Discontinuation
- 1991-10-25 CA CA002094713A patent/CA2094713A1/en not_active Abandoned
- 1991-10-25 EP EP92900519A patent/EP0554401A4/en not_active Withdrawn
- 1991-10-25 AU AU90729/91A patent/AU9072991A/en not_active Abandoned
- 1991-10-25 JP JP4501832A patent/JPH06502539A/en active Pending
- 1991-10-25 HU HU9301189A patent/HUT66445A/en unknown
-
1995
- 1995-05-22 US US08/447,214 patent/US5922325A/en not_active Expired - Lifetime
Non-Patent Citations (8)
Title |
---|
AIDS Research and Human Retroviruses, Vol. 6, No. 5, issued May 1990, ROBINSON et al., "Identification of Conserved and Variant Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 by Human Monoclonal Antibodies Produced by EBV-Transformed Cell Lines", pages 567-579, see entire document. * |
International Journal of Cancer, Vol. 37, issued 1986, SUGITA et al., "Use of a Cocktail of Monoclonal Antibodies and Human Complement in Selective Killing of Acute Lymphocytic Leukemia Cells", pages 351-357, see Title and Abstract. * |
Journal of Virology, Vol. 62, No. 11, issued November 1988, SKINNER et al., "Neutralizing Antibodies to an Immunodominant Envelope Sequence Do not Prevent gp120 Binding to CD4", pages 4195-4200, see entire document. * |
Journal of Virology, Vol. 64, No. 12, issued December 1990, OLSHEVSKY et al., "Identification of Individual Human Immunodeficiency Virus Type 1 gp120 Amino Acids Important for CD4 Receptor Binding", pages 5701-5707, see entire document, particularly Figures 1-3. * |
Journal of Virology, Vol. 64, No. 8, issued August 1990, NARA et al., "Emergence of Viruses Resistant to Neutralization by V3-Specific Antibodies in Experimental Human Immunodeficiency Virus Type 1 IIIB Infection of Chimpanzees", pages 3779-3791, see entire document, particularly the Abstract. * |
Science, Vol. 249, issued 24 August 1990, LaROSA et al., "Conserved Sequence and Structureal Elements in the HIV-1 Principal Neutralizing Determinant", pages 932-935, see entire document. * |
Science, Vol. 250, issued 14 December 1990, JAVAHERIAN et al., "Broadly Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1", pages 1590-1593, see entire document. * |
See also references of EP0554401A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197298B1 (en) | 1991-04-19 | 2001-03-06 | Tanox, Inc. | Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals |
US5872222A (en) * | 1991-04-19 | 1999-02-16 | Tanox Biosystems, Inc. | Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants |
US6106835A (en) * | 1991-04-19 | 2000-08-22 | Tanox, Inc. | Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators |
US6117982A (en) * | 1991-04-19 | 2000-09-12 | Tanox, Inc. | Conjugates of microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators |
US6129916A (en) * | 1991-04-19 | 2000-10-10 | Tanox, Inc. | Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates |
EP0588750A3 (en) * | 1992-08-05 | 1995-01-11 | Cigb | Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv. |
EP0588750A2 (en) * | 1992-08-05 | 1994-03-23 | Centro De Ingenieria Genetica Y Biotecnologia | Method for the production of recombinant polypeptides bearing epitopes from different hiv isolates, and their uses as immunogens and in the detection of antibodies against hiv |
AU684073B2 (en) * | 1993-02-24 | 1997-12-04 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
WO1995024904A1 (en) * | 1994-03-16 | 1995-09-21 | Tanox Biosystems, Inc. | Synergistic inhibition of hiv-1 infection using a nucleoside reverse transcriptase inhibitor and anti-hiv-1 antibodies |
US6420336B1 (en) | 1995-04-27 | 2002-07-16 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of using cyanovirins topically to inhibit viral infection |
US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US6743577B2 (en) | 1995-04-27 | 2004-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of using cyanovirins to inhibit viral infection |
US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US7105169B2 (en) | 1995-04-27 | 2006-09-12 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
US7754420B2 (en) | 1995-04-27 | 2010-07-13 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of using cyanovirins to inhibit viral infection |
US7339037B2 (en) | 2001-03-22 | 2008-03-04 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
EP2230250A1 (en) * | 2007-11-19 | 2010-09-22 | Kumamoto University | Anti-hiv monoclonal antibody |
EP2230250A4 (en) * | 2007-11-19 | 2012-06-27 | Univ Kumamoto | Anti-hiv monoclonal antibody |
US8722861B2 (en) | 2007-11-19 | 2014-05-13 | Kumamoto University | Monoclonal antibodies that bind to the V3 loop of HIV-1 gp120 |
Also Published As
Publication number | Publication date |
---|---|
AU9072991A (en) | 1992-05-26 |
EP0554401A4 (en) | 1996-10-30 |
EP0554401A1 (en) | 1993-08-11 |
CA2094713A1 (en) | 1992-04-27 |
US5922325A (en) | 1999-07-13 |
JPH06502539A (en) | 1994-03-24 |
HU9301189D0 (en) | 1993-07-28 |
HUT66445A (en) | 1994-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5922325A (en) | Synergistic neutralization of HIV-1 by human monoclonal antibodies and other antibodies directed against the v3 loop and the CD-4 binding site of GP-120,and the use for immunotherapy of HIV-1 infection | |
Tilley et al. | A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity | |
CA2218515C (en) | Monoclonal antibodies against hiv-1 and vaccines made thereof | |
Tilley et al. | Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120 | |
JP2520464B2 (en) | Monoclonal antibody that neutralizes HIV-1 | |
Sun et al. | Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 | |
Thali et al. | Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding | |
US5854400A (en) | Monoclonal antibodies which neutralize HIV-1 infection | |
US5834599A (en) | Immunoconjugates which neutralize HIV-1 infection | |
NZ228869A (en) | Hiv peptides, antibodies and vaccines | |
US5783670A (en) | Monoclonal antibodies specific for HIV and the hybridomas for production thereof | |
EP0492560B1 (en) | Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of HIV-1, and related peptides | |
US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
RU2128222C1 (en) | Murine monoclonal antibody nmo1, hybridoma cellular line, fragment of murine monoclonal antibody (variants) | |
Ohlin et al. | Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping. | |
JPH0768276B2 (en) | Antibodies specific for the CD4 binding region of HIV | |
US6241986B1 (en) | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV | |
De Rossi et al. | Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism | |
US6309880B1 (en) | Antibodies specific for CD4-binding domain of HIV-1 | |
US6268484B1 (en) | HIV-vaccines | |
Pinter et al. | A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates | |
US5981278A (en) | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS | |
WO1991009625A1 (en) | Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes | |
Boudet et al. | Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120 | |
Boyd et al. | B cell responses to HIV and the development of human monoclonal antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/13-13/13,DRAWINGS,REPLACED BY NEW PAGES 1/11-11/11;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2094713 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992900519 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992900519 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992900519 Country of ref document: EP |